WO2000007023A1 - Procede pour la determination de l'hepatite a virus de type c - Google Patents
Procede pour la determination de l'hepatite a virus de type c Download PDFInfo
- Publication number
- WO2000007023A1 WO2000007023A1 PCT/JP1999/004129 JP9904129W WO0007023A1 WO 2000007023 A1 WO2000007023 A1 WO 2000007023A1 JP 9904129 W JP9904129 W JP 9904129W WO 0007023 A1 WO0007023 A1 WO 0007023A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hcv
- antibody
- antigen
- surfactant
- core
- Prior art date
Links
- 241000711549 Hepacivirus C Species 0.000 title claims abstract description 122
- 238000000034 method Methods 0.000 title claims abstract description 79
- 239000000523 sample Substances 0.000 claims abstract description 77
- 239000002736 nonionic surfactant Substances 0.000 claims abstract description 8
- 239000000427 antigen Substances 0.000 claims description 143
- 108091007433 antigens Proteins 0.000 claims description 142
- 102000036639 antigens Human genes 0.000 claims description 142
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 48
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 38
- 229920001184 polypeptide Polymers 0.000 claims description 31
- 239000004094 surface-active agent Substances 0.000 claims description 30
- 108700039791 Hepatitis C virus nucleocapsid Proteins 0.000 claims description 22
- -1 dodecyldimethylammonio Chemical group 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 150000001412 amines Chemical group 0.000 claims description 8
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 claims description 7
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 229940071089 sarcosinate Drugs 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- UMWKZHPREXJQGR-UHFFFAOYSA-N n-methyl-n-(2,3,4,5,6-pentahydroxyhexyl)decanamide Chemical compound CCCCCCCCCC(=O)N(C)CC(O)C(O)C(O)C(O)CO UMWKZHPREXJQGR-UHFFFAOYSA-N 0.000 claims description 3
- 239000012190 activator Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- VICYBMUVWHJEFT-UHFFFAOYSA-N dodecyltrimethylammonium ion Chemical class CCCCCCCCCCCC[N+](C)(C)C VICYBMUVWHJEFT-UHFFFAOYSA-N 0.000 claims description 2
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 claims description 2
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 101710132601 Capsid protein Proteins 0.000 abstract description 49
- 239000003093 cationic surfactant Substances 0.000 abstract 1
- 238000001514 detection method Methods 0.000 description 56
- 238000006243 chemical reaction Methods 0.000 description 37
- 239000000243 solution Substances 0.000 description 33
- 238000012360 testing method Methods 0.000 description 32
- 239000002245 particle Substances 0.000 description 26
- 210000002966 serum Anatomy 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 20
- 208000015181 infectious disease Diseases 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 20
- 230000035945 sensitivity Effects 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 18
- 239000008280 blood Substances 0.000 description 18
- 239000008363 phosphate buffer Substances 0.000 description 16
- 239000012634 fragment Substances 0.000 description 15
- 241000700605 Viruses Species 0.000 description 14
- 239000000203 mixture Substances 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- 210000004408 hybridoma Anatomy 0.000 description 12
- 239000000126 substance Substances 0.000 description 11
- 238000005406 washing Methods 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
- 239000004202 carbamide Substances 0.000 description 8
- 238000006911 enzymatic reaction Methods 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 101710177291 Gag polyprotein Proteins 0.000 description 6
- 101710125418 Major capsid protein Proteins 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000010998 test method Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- QLAKAJLYYGOZQL-UHFFFAOYSA-N Carboxyphosphamide Chemical compound ClCCN(CCCl)P(=O)(N)OCCC(O)=O QLAKAJLYYGOZQL-UHFFFAOYSA-N 0.000 description 5
- 208000003322 Coinfection Diseases 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 5
- 229960000723 ampicillin Drugs 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 239000000306 component Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 108091006629 SLC13A2 Proteins 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000000246 agarose gel electrophoresis Methods 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000013613 expression plasmid Substances 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 229920002113 octoxynol Polymers 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 101710205625 Capsid protein p24 Proteins 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 102000003960 Ligases Human genes 0.000 description 3
- 108090000364 Ligases Proteins 0.000 description 3
- 101710177166 Phosphoprotein Proteins 0.000 description 3
- 101710149279 Small delta antigen Proteins 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 102100022563 Tubulin polymerization-promoting protein Human genes 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000011535 reaction buffer Substances 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 241000272875 Ardeidae Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229960003237 betaine Drugs 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000010836 blood and blood product Substances 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 229940125691 blood product Drugs 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000003113 dilution method Methods 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 101150111342 nol9 gene Proteins 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 2
- 238000010517 secondary reaction Methods 0.000 description 2
- 229940048098 sodium sarcosinate Drugs 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- SXOUIMVOMIGLHO-AATRIKPKSA-N (E)-3-(indol-2-yl)acrylic acid Chemical compound C1=CC=C2NC(/C=C/C(=O)O)=CC2=C1 SXOUIMVOMIGLHO-AATRIKPKSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- UMESNHVJZFCGBV-UHFFFAOYSA-N 2-methyl-4-[(2-methylphenyl)methylidene]-1,3-oxazol-5-one Chemical compound O=C1OC(C)=NC1=CC1=CC=CC=C1C UMESNHVJZFCGBV-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 241001131785 Escherichia coli HB101 Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 238000011387 Li's method Methods 0.000 description 1
- 101150039798 MYC gene Proteins 0.000 description 1
- PMTGXDAKINWIEX-UHFFFAOYSA-N N.N.N.N Chemical compound N.N.N.N PMTGXDAKINWIEX-UHFFFAOYSA-N 0.000 description 1
- 206010029719 Nonspecific reaction Diseases 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- RLGQACBPNDBWTB-UHFFFAOYSA-N cetyltrimethylammonium ion Chemical class CCCCCCCCCCCCCCCC[N+](C)(C)C RLGQACBPNDBWTB-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- UKWLRLAKGMZXJC-QIECWBMSSA-L disodium;[4-chloro-3-[(3r,5s)-1-chloro-3'-methoxyspiro[adamantane-4,4'-dioxetane]-3'-yl]phenyl] phosphate Chemical compound [Na+].[Na+].O1OC2([C@@H]3CC4C[C@H]2CC(Cl)(C4)C3)C1(OC)C1=CC(OP([O-])([O-])=O)=CC=C1Cl UKWLRLAKGMZXJC-QIECWBMSSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000003234 fluorescent labeling method Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003317 immunochromatography Methods 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- PLVPPLCLBIEYEA-UHFFFAOYSA-N indoleacrylic acid Natural products C1=CC=C2C(C=CC(=O)O)=CNC2=C1 PLVPPLCLBIEYEA-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 108700024542 myc Genes Proteins 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- CUXKZYSCZCNPNX-UHFFFAOYSA-N tetradecan-1-amine;hydrobromide Chemical compound [Br-].CCCCCCCCCCCCCC[NH3+] CUXKZYSCZCNPNX-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- AISMNBXOJRHCIA-UHFFFAOYSA-N trimethylazanium;bromide Chemical compound Br.CN(C)C AISMNBXOJRHCIA-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/18—Togaviridae; Flaviviridae
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/10—Detection of antigens from microorganism in sample from host
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
Definitions
- the present invention relates to a method for detecting hepatitis C virus (HCV), and more particularly, to a method for measuring HCV core antigen or for simultaneously measuring HCV core antigen and HCV core antibody. This method is particularly effective for screening a large number of blood samples.
- HCV hepatitis C virus
- Hepatitis caused by infection with HCV hepatitis C virus
- HCV infection can be caused mainly by blood and blood-derived components, it is possible to block the route of infection by identifying and eliminating the source of the infection.
- the method of identifying the source of infection is mainly the method of detecting antibodies to HCV polypeptide, but a method that can identify the source of infection with higher accuracy has been required.
- the required background is that there is a period after HCV infection in which antigens are present but antibodies are not produced, the so-called window period. Serum in this period cannot be used to determine the presence or absence of infection by antibody tests. Antibody tests cannot exclude samples in the period of the indo period; therefore, if blood-based substances such as blood transfusions and blood components or blood products that are screened by the antibody test are used, There is a risk of secondary infection by specimens in Therefore, HCV polypeptides It was necessary to detect HCV itself, that is, HCV particles, instead of antibodies.
- the detection and measurement of HCV itself can be performed by detecting the antigen or gene (RNA) constituting the HCV particles.
- the antigens that make up the HCV particles are considered to be the core antigen, the enveloping antigens (E1, E2).
- the envelope antigen has a high degree of mutation in a highly antigenic region as represented by a hypervariable region (Hyper Variable Region). Differences between genotypes have also been reported. To detect all of these mutations and differences, it is necessary to use a probe that specifically binds to multiple regions.
- a probe refers to a molecule that specifically binds to an antigen, such as a receptor, an antibody, a recombinant antibody, a functional molecule, or a functional structure that recognizes and binds to an antigen molecule.
- the ko antigen has a conserved sequence at the amino acid sequence level, and by selecting the region, a probe that can detect any genotype antigen of HCV for which multiple genotypes have been reported can be obtained. Because of this, it is possible to construct a genotype-independent detection method.
- a removal method there is a removal method according to a physical principle, for example, a method of separating and separating HCV particles and an antibody using a difference in molecular weight. Examples of this include gel filtration, ultracentrifugation, density gradient centrifugation, and molecular weight fractionation using membranes such as ultrafiltration membranes.
- a removal method according to a physical principle, for example, a method of separating and separating HCV particles and an antibody using a difference in molecular weight. Examples of this include gel filtration, ultracentrifugation, density gradient centrifugation, and molecular weight fractionation using membranes such as ultrafiltration membranes.
- these methods are difficult to apply to mass screening such as blood screening, because special equipment is used in the processing process.On the other hand, methods based on biochemical principles are used.
- HCV particles by changing the water environment such as PEG (polyethylene glycol), the difference in chemical properties between HCV particles and other serum components, for example, the difference in solubility in water, although there is a method of fractionation by preferentially precipitating particles, the antibody or antibody complex often precipitates in the same fraction as the particles, making it difficult to fractionate.
- HCV particles often form an immune complex of an antigen constituting the HCV particle and an antibody recognizing the same, and it is difficult to separate only the antibody or the antigen from the immune complex. .
- a method that removes substances (such as antibodies) that inhibit the function of the probe by functionally destroying them is used.
- a method of losing the function of the antibody a method of denaturing the antibody protein by exposing it to conditions for denaturing the protein can be considered. And ⁇ function of the antibody is lost, but the function of the antigen of interest, that is, the function of binding to the probe, that is, if the probe is an antibody, does not destroy the epitope, or restores the epitope. This is the condition for presentation.
- Antibody testing is a method to determine whether antibodies to HCV are present in a sample. If antibodies to HCV are present in a sample, the donor of that sample is currently infected with HCV and In some cases, HCV is present, in other cases, HCV has already been eliminated from the body by treatment or spontaneous healing, and it is difficult to distinguish them depending on the presence or absence of antibodies.
- the antigen test is an important function of notifying whether or not HCV is present in a sample or, if present, the amount of HCV, and whether or not an antibody is present at that time. Does not matter.
- HCV antibody testing can provide important information to determine whether hepatitis is the primary cause of HCV, but ultimately the presence or absence of HCV antigens is Desired. In addition, it is important to determine whether or not HCV has been eliminated from the body in order to determine the therapeutic effect, and it is important to know the amount of antigen in determining whether HCV is eliminated from the body. In other words, it is important for treatment to know the presence and amount of the antigen regardless of the presence or absence of the antibody. In other words, in treatment, it is also important to have a test method that gives the presence or absence and amount of antigen.
- test method determines whether or not there is a risk as a source of HCV infection.
- antibody testing is used as the main test method in this field.
- the window period after HCV infection Serum cannot determine the presence or absence of infection by an antibody test. Therefore, when blood-based substances such as blood transfusions, blood components, and blood products that are screened by antibody tests are used, there is a risk of secondary infection by samples in the window period. I do.
- antigen screening has not yet been performed in mass screening such as blood tests such as blood donation.
- test method that can determine the presence or absence of an antigen with a precision of 100% (sensitivity and specificity)
- sensitivity is below the detection sensitivity, it cannot be measured. Therefore, there is no inspection method that can determine with an accuracy of 100%.
- antigen testing alone may miss the source of infection, so in this field, measuring both antibodies and antigens would reduce the risk of secondary infection. is necessary.
- an antigen detection method that can be applied to mass screening and shows high sensitivity and specificity has been used, it will be necessary to measure both antigen and antibody, and the number of tests for the same number of samples will be required. Will be added more than it is now, and it will be a cost-up factor.
- the present invention provides a method for detecting an antigen in a sample at a time when an antibody is not present, such as a window period, and detecting an antigen or a antigen and an antibody in a sample at a time when an antibody is present. Provides a new test method required for testing blood and blood-derived substances.
- the present invention relates to a method for measuring hepatitis C virus (HCV), which comprises a surfactant or non-ionic surfactant having an alkyl group and a secondary to quaternary amine. It is intended to provide a method characterized by measuring an HCV core antigen by binding to its probe in the presence of an activator or both.
- HCV hepatitis C virus
- the present invention further provides a method characterized by measuring the HCV core antigen by the above-mentioned method and measuring the HCV core antibody by binding to the probe.
- Figure 1 compares the titers of the monoclonal antibodies C11-15 with those of the other monoclonal antibodies C11-3, C11-7, C11-10 and C11-14. It is a graph shown.
- FIG. 2 shows the results of ELISA when HCV-RNA positive samples were measured using various monoclonal antibodies of the present invention alone or as a mixture and immobilized on a solid phase as a primary antibody. This is the Darafu. Embodiment of the practice
- the HCV infection detection method provided by the present invention detects an antigen in a sample at a time when no antibody is present, such as a wind period phase, and detects an antigen at the time when an antibody is present, or detects both an antigen and an antibody. Is the way. That is, the antibody does not exist during the period when the antibody does not exist or during the window period, so that it is not necessary to remove the antibody when detecting the antigen. Therefore, it is not necessary to perform a pretreatment necessary for detecting the antigen.
- HCV virus particles are thought to have a structure in which the nucleic acid that is the genome and the core antigen form a complex to form particles, and the particles are covered by an outer membrane consisting of a lipid membrane and an envelope protein. Have been. Furthermore, it is thought that it exists in the blood as a complex with low-density lipoprotein (LDL) and antibodies against HCV. Therefore, the probe cannot recognize and bind to the core antigen if the virus particles are present in the blood. Therefore, in order to detect the core antigen, it is necessary to perform a treatment such as removing these structures surrounding the core antigen so that the core antigen is recognized by the probe.
- LDL low-density lipoprotein
- a reaction method comprising exposing a core antigen in an HCV particle contained in a sample so that a probe for recognizing the core antigen can be recognized, a reaction method comprising a reaction system, Also provided are reagents, including systems for reacting.
- the sample may contain an antibody against the core antigen that competes with the probe binding site, as described above. Low detection sensitivity May fall. If the core antigen is exposed so that it can bind to the probe, and if an antibody against the core antigen that competes with the probe is included, the antibody is absorbed by the exposed core antigen and the antibody is detected as an immune complex. The amount of antibody against the core antigen that binds to the antigen to be detected by the method may decrease, and the detection sensitivity may decrease.
- the antigen used for antibody detection consists of only the core antigen epitope However, they are preferably peptides or polypeptides containing HCV peptides other than the core antigen. Further, a peptide or polypeptide other than the peptide or polypeptide containing HCV peptide, which mimics HCV peptide, or a compound may be used.
- the probe for detecting the core antigen and the compound that replaces the HCV peptide or the HCV peptide do not bind by recognizing each other.
- Antibodies as probes for the HCV core antigen or labeled antibodies to detect the HCV core antigen can be used to immunize experimental animals such as mice, egrets, nits, goats, sheep, and eggs.
- variable region gene fragment obtained from cDNA or chromosomal DNA of immunoglobulin such as mouse or human, or a sequence of artificially produced cDNA or a part of chromosomal DNA of immunoglobulin.
- Variable region gene fragment constructed by combining the above, a variable region gene fragment constructed by using an artificial gene sequence, or a variable region gene produced by using these as a material by genetic recombination techniques A recombinant antibody produced by a cell transformed with a recombinant antibody gene constituted by combining the fragment with an immunoglobulin constant region gene fragment; A phage antibody produced by fusing with a structural protein of a bacterial phage; a group formed by combining the above-mentioned variable hearing-range gene fragment with another applicable gene fragment, such as a part of the myc gene. Examples include a recombinant antibody produced by a cell transformed with the recombinant antibody gene.
- Probes produced by artificially introducing a variable region into a trypsin molecule probes obtained by artificially modifying a molecule that specifically binds to a protein such as Receptor Yuichi, etc. Any molecule exhibiting high specificity and affinity for the core antigen, such as a probe produced by the combinatorial chemistry method, can be used.
- the above monoclonal antibodies can be easily prepared by those skilled in the art.
- the production of monoclonal antibodies by hybridomas is well known.
- the fusion polypeptide or polypeptide (hereinafter referred to as “the present antigen”) alone or in combination with BSA, KLH or the like is intraperitoneally or intradermally in a BALBZc mouse or the like.
- Regular immunization is performed by mixing with an adjuvant such as simple or Freund's complete adjuvant as an antigen.
- an adjuvant such as simple or Freund's complete adjuvant as an antigen.
- this antigen is administered to the tail vein as a booster, the spleen is removed aseptically, and the cell is fused with an appropriate mouse myeloma cell line. Get Puri Dorma.
- This method can be performed according to the method of Kohler and Milstein (Nature 256: 495-497, 1975).
- the hybridoma cell line obtained by the above method is cultured in an appropriate culture medium, and then a hybridoma cell line that produces an antibody showing a specific reaction to the antigen is selected and cloned. I do.
- Cloning of antibody-producing hybridomas can be carried out by limiting a dilution method or by a soft agar method (Eur. J. Immunol. 6: 511-519, 1976). Then, the produced monoclonal antibody is purified by a method such as column chromatography using protein A or the like.
- Molecules to be used as probes other than the above-mentioned monoclonal antibodies can be prepared.
- recombinant antibodies are described in detail in a review by Hoogenboon (Trends in Biotechnology, 15:
- the antigen as a probe for the HCV core antibody in the sample or the antigen for producing the HCV core antibody is specifically, for example, an amino acid represented by SEQ ID NO: 1 or 2.
- a polypeptide having a sequence or a fusion polypeptide containing a plurality of amino acid sequences described in SEQ ID NOs: 3 to 6, which can be obtained by recombinant expression of DNA encoding these. Can be.
- the detection principle may be an enzyme-labeled antibody method, a fluorescent labeling method, a radioisotope labeling method, or any other method used in ordinary immunoassays. Examples include colorimetry, fluorescence, and chemiluminescence.
- a method generally used for antibody detection such as a two-antigen sandwich method, may be used, and for antigen detection, a one-step sandwich method may also be used. It is also possible to use a method such as a system.
- One embodiment of the present invention is the following reaction system.
- a probe against the HCV core antigen for example, an antibody against the HCV core antigen
- a compound containing the HCV epitope for example, an HCV polyantigen.
- Peptides including peptide peptides, peptide compounds or polypeptides, and mixtures thereof, can be added to carriers used in immunoassays, such as microplates. Immobilize. A component that exposes the solid-phased carrier so that the probe can recognize the HCV core antigen from the HCV particles or particle complex, and does not inhibit the function of the antibody against the HCV epitope.
- the reaction with the sample is carried out in a reaction buffer containing, and the core antigen and the antibody against the HCV epitope contained in the sample are specifically bound to the carrier.
- unbound components in the sample are removed, for example, by washing the carrier with an appropriate buffer, and then labeled with a probe that recognizes the core antigen bound to the carrier, such as an enzyme for the core antigen.
- a probe that recognizes the core antigen bound to the carrier such as an enzyme for the core antigen.
- the labeled antibody By reacting the labeled antibody with a probe that recognizes the antibody to HCV epitope bound to the carrier, for example, a reaction solution containing an anti-human antibody mouse monoclonal antibody labeled with an enzyme or the like. Specifically, the antibody binds specifically to the core antigen bound to the carrier and an antibody against the HCV epitope.
- the core antigen and HCV peptide contained in the sample are removed by removing the unreacted components, for example, by washing the carrier with an appropriate buffer and detecting the label by an appropriate method. It is possible to detect an antibody against one step.
- the reaction system suitable for antigen detection in the system provided by the present invention refers to a complex structure present in a sample under mild conditions that does not impair the function of an antibody against HCV antigen epitope. From the body HCV particles, an antibody that is a probe that recognizes the HCV antigen is identified. It is a system consisting of conditions that sufficiently expose the region to be perceived.
- Virus particles already separated by ultracentrifugation (Takahashi et al., 1996, J. Gen. virol, 73: 667-672), and HCV particles aggregated and precipitated with polyethylene glycol
- a non-ionic surfactant such as Tween 800 or Triton X 100 (Kashiwakuma et al., 1996, J. Immunological methods 190: 79-89)
- the core antigen was The former, which has been shown to be detectable, has insufficient detection sensitivity, and it is questionable whether the antigen is sufficiently exposed. In the latter, the antibody is inactivated by adding another treating agent, and the effect of the surfactant itself is not mentioned.
- the conditions are examined on the basis of a surfactant, and the reaction solution is made to have a composition centered on the surfactant. It is now possible to efficiently detect antigens in HCV particles simply by diluting the sample in the reaction solution without applying a pretreatment method consisting of operations such as operation and heating. .
- surfactants in this case include surfactants having an alkyl group and secondary to quaternary amines in the same molecule, or nonionic surfactants.
- the alkyl group is preferably a straight-chain alkyl group, and preferably has 10 or more carbon atoms. More preferably, the 12- to 16-members are preferably the third or fourth members (ammonium).
- Specific surfactants include dodecyl-N-sarcosine Acid, perdodecyl triammonium ammonium salt, cetyl trimethylammonium salt, 3 — (dodecyldimethylammonio) — 1 1-prosulfuronic acid, 3 — (tetradecyldimethylammonio) — 1 — punculsulfonic acid , Dodecyl bilidium salt, cetyl pyrimidium salt, decanoyl- ⁇ -methylglucamide (MEGA-10), dodecyl-1-N-betaine and the like. Dodecyl-N-sarcosinate and dodecyl trimethylampinium salt are preferred.
- nonionic surfactant those having a hydrophilic-hydrophobic ratio of 124 are preferable, and polyoxyethyleneisooctylphenyl ethers such as Triton X100 Triton X11 4, or polyoxyethylene noniphenyl ethers such as Nonidetp 40, Triton NlOl. Nikko 1 NP are preferred.
- the above two types of surfactants may be used alone, but they are preferably used in combination, and a synergistic effect can be obtained by using them in combination.
- an antigen containing an HCV epitope, a carrier on which an antibody for detecting the HCV antigen is immobilized, and a reaction solution provided by the present invention are used so as to detect an antibody against the HCV epitope.
- the antigen is efficiently detected in the sample containing HCV antigen without HCV antibody, and the antibody is efficiently detected in the sample containing only antibody without HCV antigen.
- Antibody was detected, and it was found that in a sample in which an antigen and an antibody were present, a high signal was given by simultaneously detecting the antigen and the antibody.
- a method for simultaneous detection of the virus antigen and an antibody against the virus antigen involves detecting p24, which is a gag protein, as an antigen test, and using an enve1 op protein and a part of the gag protein as an antibody test. This is achieved by combining methods for detecting an antibody against a certain p19.
- the virus antigen and the antibody against the virus antigen are simultaneously detected.
- Establishing a detection method is relatively easy. This is because, for example, in the case of an HIV test, a probe used for detecting an antigen, for example, an antigen p24 recognized by a monoclonal antibody against an HIV epitope, and an antibody contained in a subject sample in an antibody test.
- the monoclonal antibody against the core antigen used for antigen detection binds to the core antigen used for antibody detection, is absorbed, and the detection sensitivity of the antigen in the sample is increased.
- problems such as a decrease, binding to an antigen used for antibody detection, inducing a nonspecific reaction in an antigen test, and a decrease in sensitivity due to masking of an HCV epitope for an antibody test.
- the inventors of the present invention divide the epitope of a monoclonal antibody used for antigen detection and the epitope of an antibody against a core antigen present in a subject into different types. As a result, they have found that an antigen and an antibody can be efficiently detected simultaneously, and have completed the present invention.
- the results of various epitope analysis showed that the most important region was the N-terminus of the core antigen, especially from the first place of HCV polypeptide. It has been shown to be at position 0 (Okamoto et al, Hapatology 15: 180-186, 1992, Sallbe rg et al, J. Clinical. Microbiol., 30: 1989-1994, 1992, Sallsbe rg et al. , J Med. Vilol, 43: 62-68, 1994).
- genotype-specific peptides are located at positions 66 to 80 of the HCV polypeptide (Machida Hepatology 16: 886-891 '92, Japanese Patent Application No. 9-200). 9 2 2). Therefore, it is important to have the sequence from position 1 to position 40 and from position 66 to position 80 of the HCV polypeptide as an antigen for detecting an antibody against the HCV polypeptide. It is. Therefore, as an antigen for detecting an HCV antibody, an antigen including a sequence from position 1 to position 42 and a sequence from position 66 to position 80 of HCV polypeptide CEPM is an antigen polypeptide having a suitable sequence. It is disclosed in the examples as peptides.
- CEPM is an antigen consisting of a human sequence in which the following regions of the HCV polypeptide are arranged in the following order, and the construction method thereof is described in Japanese Patent Application No. 9-2095252. The sequence is set forth in SEQ ID NO: 10. List of CEPM HCV topologies:
- a monoclonal antibody that recognizes and binds to a region where the antibody against the core antigen is not specifically present in the subject, that is, from position 100 to position 130 of the HCV polypeptide is first used.
- the recognition site of the secondary antibody for detecting the core antigen bound to the primary antibody is a region not used for the antibody test, from position 40 to position 5 of the HCV polypeptide.
- core antigens retained by antibodies to positions 100 to 130 of the HCV polypeptide are detected.
- An expression plasmid corresponding to the core region of HCV was constructed by the following method.
- a plasmid p UC obtained by incorporating C ll — C 21 clone and CIO — E 12 clone (Japanese Patent Laid-Open No. 6-388765) into p UC 119.
- the 0RI-C1aI fragment and the approximately 920 bp C1aI-KpnI fragment were purified.
- the two DNA fragments and pUCl19 were digested with EcoRI and KpnI in a 10X ligase buffer [660 mM Tr
- PCR was performed using a GeneAmpTM (DNA Amplification Reagent Kit, manufactured by Perkin Elmer Cetus) DNA denaturation 95 ° C 1.5 minutes, annealing 50 ° C 2 minutes, DNA synthesis 70 ° C 3 minutes Under the conditions, the obtained DNA fragment was digested by 0.8% agarose gel electrophoresis, and purified by a glass powder method (Gene Clean).
- GeneAmpTM DNA Amplification Reagent Kit, manufactured by Perkin Elmer Cetus
- pUC19 was digested with the restriction enzyme SmaI, and the DNA fragment obtained by the PCR method was digested with a 10X ligase buffer [660 mM Tris-HC1 (pH 7. 5), 6 6 mM M g C 1 2, 1 0 0 mM Jichio Threshold Level preparative Ichiru, I mM ATP] 5 ii, of T 4 rigger Ichize 1 1 (3 5 0 units Z mu 1) in water
- the temperature was adjusted to 50/1, and the temperature was maintained at 16 ° C overnight, and the coupling reaction was performed.
- Escherichia coli JM109 was transformed using this plasmid to obtain a plasmid pUC19-C21-E12 ⁇ SmaI.
- Ec0RI-BamHI-treated vector DNA (1 g) and the above-mentioned core 140 fragment were combined with a 10X ligase buffer [660 mM Tris-HC1 (pH 7.0. 5), 6 6 mM M g C 1 2, 1 0 0 mM Jichiosu Les preparative Lumpur, 1 mM ATP) 5 1, T 4 rigger Ichize (3 5 0 units Z l) was added with water 5 0 The mixture was incubated at 16 ° C. overnight, and ligation was performed. Using 101 of this reaction mixture, Escherichia coli HB101 was transformed. Sensitive E.
- coli strains used for transformation are prepared by the calcium chloride method [Mandel, M. and Higa, A., J. Mol. Biol., 53, 159-162 (1970)].
- the transformed E. coli was spread on an L-plate (1% tripton, 0.5% NaCl, 1.5% agar) containing 25 g Zml of ampicillin. Incubated at 37 ° C overnight.
- One platinum loop of the bacterial colonies formed on the plate was taken, transferred to an LB medium containing 25 g Zml of ampicillin, and cultured at 37 ° C overnight.
- 0 1 strain was inoculated into 3 ml of 2YT medium (1.6% tripton, 1% yeast extract, 0.5% NaC1) containing 50 / ig Zml of ampicillin. Incubate at 37 ° C for 9 hours.
- This culture solution 1 ml 5 0 g / ml of ⁇ Npishi 1 including re down 0 O ml of M 9 - CA medium (0. 6% N a 2 HP_ ⁇ 4, 0. 5% KH 2 PO 4, 0 .5% NaCl, 0.1%
- the cells were suspended in 2 O ml of buffer A (5 OmM Tris-HCl (pH 8.0), 1 mM EDTA, 30 mM NaC1), and centrifuged again. 2.6 g of the expressed cells were obtained. The obtained cells were suspended in 10 ml of buffer A, and the E. coli membrane was disrupted by sonication, followed by centrifugation. The fusion polypeptide of the polypeptide encoded by HCV cDNA and TrpE was synthesized. Was obtained. To the fraction was added 10 ml of buffer A containing 6 M urea to solubilize and extract the fusion polypeptide. The solubilized extract was subjected to ion-exchange column chromatography using S-Sephar0se to purify the fusion polypeptide.
- buffer A 5 OmM Tris-HCl (pH 8.0), 1 mM EDTA, 30 mM NaC1
- TrpC11 fusion polypeptide
- the solution was terminated in 10 mM phosphate buffer (H7.3) containing 0.15 MNaCl. It was diluted to a concentration of 1.0 mgZml and mixed with an equal amount of evening Max to make a TrpC11 suspension.
- the suspension prepared so that the T rp C 11 concentration is from 0.01 to 0.05 mgZml. was administered intraperitoneally to BALBZ c mice 4-6 weeks old. About 8 weeks later, the immunized animal was administered a saline solution prepared so that the TrpC11 concentration was 0.05 to 0.03 mgZml via the tail vein.
- the spleen was aseptically removed from the immunized animal, sectioned with scissors, dissociated into individual cells using a mesh, and RPMI-1 Washing was performed three times with 64 medium. 8—Cultured in the presence of azaguadin for several days, and the mouse myeloma cell line PAI in the logarithmic growth phase from which the revertants were completely removed was washed in the same manner as described above. Seven and 1.0 ⁇ 10 8 spleen cells were placed in a 50 ml centrifuge tube and mixed.
- the fused cells are treated with hypoxanthine, aminopterin and thymidine (hereinafter abbreviated as HAT) using 96-well plate.
- HAT hypoxanthine, aminopterin and thymidine
- the hybridomas were grown by culturing for 1-2 weeks in RPMI_164 medium containing Thereafter, the cells are grown in a medium containing no HAT, and after about two weeks, clones producing the desired antibody are searched by ELISA to produce the monoclonal antibody of the present invention having the desired reaction specificity. I got High Puri Doma.
- the obtained hybridomas were searched for the target antibody-producing strain and subjected to single cloning in accordance with a standard limiting dilution method, and the obtained hybridomas were used as HC11--14. , HC11-1-10, HC11-3, and HC11-7.
- the hybridoma obtained by the method described in Example 2 was transplanted into the abdominal cavity of a mouse treated with pristane or the like to obtain a monoclonal antibody produced in ascites.
- an IgG fraction was separated using a Sepharose column to which protein A was bound.
- Monoclonal antibodies produced from the above five hybridomas, C11-1-14, C11-1-10, C11-7 and C11-3 isotypes C11-11 and C11-7 were obtained by double immunodiffusion method using Egret anti-mouse Ig isotype antibodies (Zymed), and IgG2a, C11-1 14 and C 1 1 — 3 were found to be IgG 1.
- Table 1 shows the results of an analysis of the four types of monoclonal antibodies obtained using 20 peptides synthesized from sequences derived from the HCV and core regions. As can be seen, it is a monoclonal antibody that specifically recognizes a part of the core region.
- Example 4 Method for detecting antigen efficiently without pretreatment
- a sample containing HCV particles is diluted in a reaction solution containing a surfactant.
- the detection efficiency of the HCV core antigen was examined.
- the detection of the HCV core antigen was performed by a sandwich enzyme immunoassay (EIA) using a monoclonal antibody against the HCV core antigen.
- EIA sandwich enzyme immunoassay
- C 11-3 and CI 1-7 were used as antibodies to supplement the core antigen, and CI 11-10 and C 11-14 were supplemented. It was used as an antibody to detect the extracted core antigen.
- EIA was performed basically under the following conditions.
- a solution prepared by diluting each of the monoclonal antibodies C11-3 and C11-17 to 4 g Zml in an acetate buffer was added to a microtiter plate, and incubated at 4 ° C overnight.
- the cells were washed with a phosphate buffer and subjected to a blocking operation by adding a phosphate buffer containing 1% BSA.
- the reaction solution 1001 and the sample 100 ⁇ 1 were added thereto, and the mixture was stirred and reacted at room temperature for 1.5 hours. After removing unreacted substances by washing with a phosphate buffer containing a low-concentration surfactant, the monoclonal antibody C111 labeled with alkaline phosphatase was used.
- n-octyltrimethylammonium chloride 0.5 1.00 0.75 0.99
- Nonionic MEGA- 10 0.5 3.38
- Example 5 Detection of core antigen in a sample before HCV antibody emergence (wind period) after HCV infection
- the sales outlet conversion panel PHV 905 (B.B.I. inc.) was mixed with 2% Triton X 100 and 2% dodecyl N-sarcosinate in the reaction mixture. The measurement was carried out according to Example 4 by adding sodium.
- the PHV 905 panel used here showed positive conversion by anti-HCV antibody test (ortho EI A. 3.0) on day 21 (sera No. PHV 905-7) after the start of observation.
- the antibody titer is expressed by a cut-off index (SZCO), and a value of 1.0 or more is determined to be positive.
- the HCV core antigen activity was expressed as a ratio (SZN) to the light emission amount of healthy human serum as 1.0.
- the core antigenic activity was observed before the anti-HCV antibody was still positive, and the addition of this surfactant exposed the core antigenicity from the virus particles and immobilized it. Reacted with monoclonal antibodies It was confirmed that detection was possible.
- Example 6 Detection of HCV antibody contained in a sample and simultaneous detection with core antigen
- Antibodies against HCV epitope were inactivated in the primary reaction solution containing surfactant using a sample (human serum) containing antibodies to HCV epitope and containing almost no HCV antigen. Without binding to the HCV polypeptide, and can be detected by adding an anti-human antibody to the secondary reaction solution.In addition, if a core antigen is present, the core antigen is detected. The following method was used to confirm that the antibody was detectable when an antibody against HCV epitope was included, and that the antibody was detectable when both were included.
- EIA was basically performed under the following conditions. Dilute the recombinant antigen containing the HCV epitope, CEPM, in phosphate buffer containing urea, add it to a microtiter plate, and incubate at 4 ° C overnight. Wash with phosphate buffer Then, the monoclonal antibody C11-3, C11-7 is added to the plate with acetic acid ⁇
- the solution diluted in the buffer was added, and the mixture was kept at 4 ° C overnight.
- the method for preparing the recombinant antigen CEPM is described in Japanese Patent Application No. 9-209525. After removing the antibody solution, the cells were washed with a phosphate buffer and subjected to a blocking operation by adding a phosphate buffer containing 1% BSA.
- HCV antibody-positive human serum which has been confirmed to contain almost no HCV core antigen, was diluted with sera and used as a sample to confirm that antibodies to HCV epitope were detected. As a result, it was confirmed that the antibody reacted in a concentration-dependent manner, and that the antibody was detected without being inactivated in the primary reaction solution.
- Example 7 Method for measuring antigen and antibody in human serum Using a healthy human sample, a patient sample, and a seroconversion panel sample (BBI inc.), The antigen and antibody were simultaneously measured according to the method described in Example 6. For panel sera, comparisons were made with the results of determination using HCV antibody detection reagents provided by the vendor.
- BBI inc. seroconversion panel sample
- Table 6 shows the results of measurement using 18 samples from healthy subjects, and it was confirmed that there was no reaction to healthy subjects. Based on the distribution of healthy subjects, the discriminating value between positive and negative was set to 0.1.
- Example 9 Monoclonal antibody titer assay
- the recombinant core antigen (Trpc11) was diluted to a final concentration of 2 g Zml in 10 mM phosphate buffer (pH 7.3) containing 6 M urea, and each well of the microplate was diluted. Was added at a time. After allowing to stand at 4 ° C for a while, aspirated and washed twice with 10 mM phosphate buffer (pH 7.3). 350 mM phosphate buffer (pH 7.3) containing 0.5% casein was added in 3501 portions, and the mixture was incubated at room temperature for 1 hour, and then aspirated.
- Each monoclonal antibody (C11-13, C11-7, C11-10, C11-14 or C11-14) serially diluted with the reaction solution is added to each well, and reacted for 1 hour.
- a peroxidase-labeled anti-mouse antibody was added and reacted for 30 minutes.
- a substrate solution containing ortho-phenylenediamine and hydrogen peroxide was added to carry out an enzyme reaction. After reacting at room temperature for 30 minutes, the enzyme reaction was stopped by adding 2 N sulfuric acid, and the absorbance at 492 nm was measured with a microplate reader.
- Figure 1 shows the results.
- C11-15 has the highest antibody titer, indicating that it can be detected with high sensitivity when used as a secondary antibody.
- Monoclonal antibodies (C11-3 and C11-5 and C11-15; C11-3 and C11-17; C11-3 and C11-15; C11-3 alone; Dilute C11-17 alone; or C11-15 alone) in 10 mM phosphate buffer (pH 7.3) to a final concentration of 6 ⁇ l, and add to each well of the microplate. One hundred and one were added. After allowing to stand at 4 ° C, the mixture was aspirated and washed twice with 10 mM phosphate buffer (PH 7.3). 10 mM phosphate buffer (pH 7.3) containing 0.5% casein was added at 350/1 each, and the mixture was incubated at room temperature for 2 hours and aspirated.
- HCV RNA positive Then, CV antibody-negative sample 1001 and reaction solution 1001 were added to each well, and reacted at room temperature for 1 hour. After washing, a peroxidase-labeled anti-core antigen monoclonal antibody (mixture of C11-14 and c11-10) is added and reacted for 30 minutes. After washing, orthopentadiamine and hydrogen peroxide are added. Is added and the enzyme reaction is performed. After reacting at room temperature for 30 minutes, 2N sulfuric acid was added to stop the enzyme reaction, and the absorbance at 492 nm was measured with a microplate reader. Figure 2 shows the results.
- the E. coli transformant CEP MZH B101 strain was cultured at 37 ° C overnight in an LB medium containing 10 O ⁇ g Zml ampicillin. This was inoculated into M9-CA containing 100 ⁇ g Z ml ampicillin at 1% concentration, 37. C The cells were cultured overnight. After completion of the culture, the cells were collected by centrifugation, and resuspended in 5 O ml Lysis solution [50 mM Tris-HC1 (pH 8.5), 30 mM NaC1, 5 mM EDTA]. 1 ml of lysozyme solution (10 mgZ ml Lysozyme) was added, and the mixture was treated at 37 ° C for 1 hour.
- the suspension was subjected to sonication (150 W, twice for 90 seconds) to destroy the cells.
- Insoluble fraction was collected by centrifugation at 1500 rpm at 4 ° C for 30 minutes.
- the insoluble fraction was resuspended in 5 O ml of an A solution (50 mM Tris-HC1 (pH 8.5)) containing 1% of NP40 and homogenized (5 tubes at 150 O rpm). Rourke)
- the suspension was centrifuged at 1500 rpm at 4 ° C for 30 minutes to collect the insoluble fraction.
- the insoluble fraction was resuspended in 50 ml of A solution containing 2 M urea and homogenized (5 strokes at 150 O rpm). Suspension at 1500 O rpm so,?
- the mixture was centrifuged at 4 ° C for 30 minutes to collect an insoluble fraction.
- the insoluble fraction was resuspended in 50 ml of A solution containing 6 M urea and homogenized (5 strokes at 1500 rpm).
- the suspension was centrifuged at 1500 rpm at 4 ° C. for 30 minutes to collect the soluble fraction.
- nucleotide sequence of the DNA encoding the chimeric antigen is shown in SEQ ID NO: 10 and the amino acid sequence of the chimeric antigen is shown in SEQ ID NO: 11 Deposited under Rule 13bis of the Patent Cooperation Treaty References to deposited microorganisms and depository institutions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/509,449 US7316905B1 (en) | 1998-07-30 | 1999-07-30 | Method for measurement of hepatitis C virus |
JP2000562761A JP3514729B2 (ja) | 1998-07-30 | 1999-07-30 | C型肝炎ウイルスの測定方法 |
DE69939811T DE69939811D1 (de) | 1998-07-30 | 1999-07-30 | Verfahren zur bestimmung von hepatitis c viren |
BR9906660-2A BR9906660A (pt) | 1998-07-30 | 1999-07-30 | Processo para medir vìrus da hepatite c |
EP99933204A EP1020727B1 (en) | 1998-07-30 | 1999-07-30 | Method for assaying hepatitis c virus |
CA002305192A CA2305192C (en) | 1998-07-30 | 1999-07-30 | Method for assaying hepatitis c virus |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10/216094 | 1998-07-30 | ||
JP21609498 | 1998-07-30 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/509,449 A-371-Of-International US7316905B1 (en) | 1998-07-30 | 1999-07-30 | Method for measurement of hepatitis C virus |
US10/133,007 Division US6623921B2 (en) | 1998-07-30 | 2002-04-26 | Method for measurement of hepatitis C virus |
US10/133,007 Continuation US6623921B2 (en) | 1998-07-30 | 2002-04-26 | Method for measurement of hepatitis C virus |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000007023A1 true WO2000007023A1 (fr) | 2000-02-10 |
Family
ID=16683164
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1999/004129 WO2000007023A1 (fr) | 1998-07-30 | 1999-07-30 | Procede pour la determination de l'hepatite a virus de type c |
Country Status (11)
Country | Link |
---|---|
US (1) | US7316905B1 (ja) |
EP (1) | EP1020727B1 (ja) |
JP (1) | JP3514729B2 (ja) |
KR (1) | KR100847586B1 (ja) |
CN (1) | CN1274424A (ja) |
AT (1) | ATE412904T1 (ja) |
BR (1) | BR9906660A (ja) |
CA (1) | CA2305192C (ja) |
DE (1) | DE69939811D1 (ja) |
ES (1) | ES2313787T3 (ja) |
WO (1) | WO2000007023A1 (ja) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004506878A (ja) * | 2000-06-15 | 2004-03-04 | カイロン コーポレイション | Hcv抗原/抗体の組合せアッセイ |
US7101683B2 (en) * | 2001-06-26 | 2006-09-05 | Abbott Laboratories | Methods for the simultaneous detection of HCV antigens and HCV antibodies |
WO2007049394A1 (ja) * | 2005-10-25 | 2007-05-03 | Kurume University | C型肝炎ウイルス由来ペプチド |
US7410802B2 (en) | 1999-07-30 | 2008-08-12 | Bioe, Inc. | Methods for simultaneously detecting both members of a binding pair |
US8546075B2 (en) * | 2003-10-28 | 2013-10-01 | Advanced Life Science Institute, Inc. | Method of detecting hepatitis C virus |
US9194873B2 (en) | 2013-03-14 | 2015-11-24 | Abbott Laboratories | HCV antigen-antibody combination assay and methods and compositions for use therein |
WO2017065261A1 (ja) * | 2015-10-15 | 2017-04-20 | 富士レビオ株式会社 | ヒトパルボウイルスb19抗原および抗体の同時検出方法及びキット |
US9790478B2 (en) | 2013-03-14 | 2017-10-17 | Abbott Laboratories | HCV NS3 recombinant antigens and mutants thereof for improved antibody detection |
US10197573B2 (en) | 2013-03-14 | 2019-02-05 | Abbott Laboratories | HCV core lipid binding domain monoclonal antibodies |
JP2019522188A (ja) * | 2016-05-31 | 2019-08-08 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Hcvコア抗原の迅速な検出のための前処理法 |
JP2019523863A (ja) * | 2016-05-31 | 2019-08-29 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ウイルス抗原の血清学的検出方法 |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU785380B2 (en) * | 2001-03-28 | 2007-03-15 | Ortho-Clinical Diagnostics, Inc. | A hepatitis C antigen - antibody combination assay for the early detection of HCV infection |
CA2450710C (en) * | 2001-06-26 | 2013-11-26 | Abbott Laboratories | Methods for the simultaneous detection of hcv antigens and hcv antibodies |
US20030108563A1 (en) * | 2001-11-07 | 2003-06-12 | Chander Bahl | Reagents for the simultaneous detection of HCV core antigens and antibodies |
US7332269B2 (en) * | 2001-11-11 | 2008-02-19 | Ortho-Clinical Diagnostics, Inc. | HCV core protein sequences |
US20040152070A1 (en) * | 2003-02-04 | 2004-08-05 | Shah Dinesh O. | Method of detection of HCV antibodies in combination assay or sole antibody assay |
KR20070012838A (ko) * | 2004-05-19 | 2007-01-29 | 가부시끼가이샤 센단세메이가가꾸겐큐죠 | B형간염 바이러스의 검출방법 |
GB0522193D0 (en) | 2005-10-31 | 2005-12-07 | Axis Shield Asa | Method |
ES2303496B1 (es) * | 2008-02-21 | 2009-07-07 | Fundacion Para El Estudio De Las Hepatitis Virales | Metodo analitico perfeccionado para la deteccion de hepatitis c oculta, aplicaciones del mismo y su correspondiente kit de diagnostico. |
FR2984328B1 (fr) | 2011-12-20 | 2016-12-30 | Bio-Rad Innovations | Procede de detection d'une infection par le virus de l'hepatite c |
US9891225B2 (en) | 2013-05-10 | 2018-02-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for simultaneous detection of HCV antigen/antibody |
CN103675280B (zh) * | 2013-12-17 | 2015-05-20 | 山东博科生物产业有限公司 | 一种检测丙肝核心抗原的标记物及试剂 |
CN103630690B (zh) * | 2013-12-17 | 2014-08-20 | 朱之炜 | 丙型肝炎病毒抗原抗体联合检测试剂盒及其检测方法 |
CN104849460A (zh) * | 2015-05-29 | 2015-08-19 | 山东博科生物产业有限公司 | 一种稳定的丙型肝炎病毒核心抗原酶结合物稀释液 |
CN106093402A (zh) * | 2016-05-31 | 2016-11-09 | 湖南康润药业有限公司 | 丙型肝炎病毒抗原抗体联合检测试剂盒 |
CN113552358B (zh) * | 2021-09-03 | 2024-08-30 | 郑州安图生物工程股份有限公司 | 一种hcv病毒裂解剂及其制备方法、hcv病毒检测试剂盒 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6024451A (ja) * | 1983-06-08 | 1985-02-07 | アクゾ・エヌ・ヴエ− | 体液中のデルタ抗原決定 |
JPH085633A (ja) * | 1994-06-16 | 1996-01-12 | Dainabotsuto Kk | 特異的IgM抗体の測定法及びその試薬 |
US5616460A (en) * | 1995-06-07 | 1997-04-01 | Abbott Laboratories | Buffer composition for reagents for immunoassay |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4148869A (en) | 1975-03-06 | 1979-04-10 | Baxter Travenol Laboratories, Inc. | Immunological reagent and method of using same |
CA1148859A (en) * | 1979-06-14 | 1983-06-28 | Lacy R. Overby | Simultaneous assay of two hepatitis viruses using a solid phase |
JPH0610723B2 (ja) | 1983-06-23 | 1994-02-09 | コニカ株式会社 | カラーネガフィルムの撮像装置 |
GB8317855D0 (en) * | 1983-06-30 | 1983-08-03 | Iq Bio Ltd | Biochemical detection method |
DE3327642A1 (de) * | 1983-07-30 | 1985-02-14 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verfahren zur bestimmung eines partners einer immunreaktion sowie reagens zur durchfuehrung dieses verfahrens |
ZA855031B (en) * | 1984-08-31 | 1986-02-26 | New York Blood Center Inc | Assay for simultaneous detection of antigen and antibody in given serum |
JPS6415656U (ja) | 1987-07-17 | 1989-01-26 | ||
US5032503A (en) * | 1988-06-22 | 1991-07-16 | Microgenics Corporation | Liquid single reagent for air enzyme complementation assay |
CA1335880C (en) * | 1988-07-14 | 1995-06-13 | Thomas P. O'connor | Detection of an antibody and antigen in an immunoassay |
JP3195799B2 (ja) | 1990-12-20 | 2001-08-06 | 株式会社先端生命科学研究所 | 非a非b型肝炎ウイルス構造蛋白質をコードするdna断片 |
CA2101056A1 (en) | 1991-01-25 | 1992-07-26 | Adrienne L. Gilbert | Use of superoxide dismutase in specimen diluent |
US5574132A (en) * | 1991-04-05 | 1996-11-12 | Biochem Immunosystems Inc. | Peptides and mixtures thereof for detecting antibodies to hepatitis C virus (HCV) |
DE4209215A1 (de) * | 1991-07-04 | 1993-01-07 | Boehringer Mannheim Gmbh | Hcv peptidantigene und verfahren zur bestimmung von hcv |
US5525461A (en) * | 1991-11-01 | 1996-06-11 | T Cell Diagnostics, Inc. | Therapeutic and diagnostic methods using total leukocyte surface antigens |
JP2001504572A (ja) * | 1992-04-09 | 2001-04-03 | アボツト・ラボラトリーズ | Hiv抗原及びhiv抗体を検出するためのアッセイ |
IT1257192B (it) * | 1992-05-26 | 1996-01-10 | Gilardini Spa | Gruppo retrovisore per un veicolo. |
JP2778886B2 (ja) * | 1992-10-16 | 1998-07-23 | エバーニュー バイオテック インコーポレイティド | C型肝炎ウィルスのコア抗原タンパク質及びそれを用いての診断方法及びキット |
JPH06300761A (ja) | 1993-04-19 | 1994-10-28 | Eiken Chem Co Ltd | 免疫比濁測定試薬及び測定方法 |
US5843450A (en) * | 1994-02-14 | 1998-12-01 | Abbott Laboratories | Hepatitis GB Virus synthetic peptides and uses thereof |
US5627080A (en) * | 1994-07-29 | 1997-05-06 | Beckman Instruments, Inc. | Detergent-facilitated immunoassay for the rapid and quantitative assay of pharmacological agents |
JPH0850133A (ja) | 1994-08-05 | 1996-02-20 | Toray Ind Inc | 免疫化学的測定方法 |
GB2313666A (en) * | 1996-05-28 | 1997-12-03 | Hoffmann La Roche | Assay for detecting HIV antigens and HIV antibodies |
JP3171827B2 (ja) | 1997-08-04 | 2001-06-04 | 株式会社先端生命科学研究所 | ウイルスの検出又は測定方法 |
EP0967484B1 (en) * | 1997-08-04 | 2007-05-02 | Advanced Life Science Institute, Inc. | Methods for detecting or assaying virus |
-
1999
- 1999-07-30 JP JP2000562761A patent/JP3514729B2/ja not_active Expired - Lifetime
- 1999-07-30 US US09/509,449 patent/US7316905B1/en not_active Expired - Lifetime
- 1999-07-30 KR KR1020007003410A patent/KR100847586B1/ko not_active IP Right Cessation
- 1999-07-30 CA CA002305192A patent/CA2305192C/en not_active Expired - Lifetime
- 1999-07-30 ES ES99933204T patent/ES2313787T3/es not_active Expired - Lifetime
- 1999-07-30 AT AT99933204T patent/ATE412904T1/de not_active IP Right Cessation
- 1999-07-30 DE DE69939811T patent/DE69939811D1/de not_active Revoked
- 1999-07-30 CN CN99801248A patent/CN1274424A/zh active Pending
- 1999-07-30 EP EP99933204A patent/EP1020727B1/en not_active Revoked
- 1999-07-30 WO PCT/JP1999/004129 patent/WO2000007023A1/ja not_active Application Discontinuation
- 1999-07-30 BR BR9906660-2A patent/BR9906660A/pt not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6024451A (ja) * | 1983-06-08 | 1985-02-07 | アクゾ・エヌ・ヴエ− | 体液中のデルタ抗原決定 |
JPH085633A (ja) * | 1994-06-16 | 1996-01-12 | Dainabotsuto Kk | 特異的IgM抗体の測定法及びその試薬 |
US5616460A (en) * | 1995-06-07 | 1997-04-01 | Abbott Laboratories | Buffer composition for reagents for immunoassay |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7410802B2 (en) | 1999-07-30 | 2008-08-12 | Bioe, Inc. | Methods for simultaneously detecting both members of a binding pair |
JP2004506878A (ja) * | 2000-06-15 | 2004-03-04 | カイロン コーポレイション | Hcv抗原/抗体の組合せアッセイ |
JP4834279B2 (ja) * | 2000-06-15 | 2011-12-14 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | Hcv抗原/抗体の組合せアッセイ |
JP4837229B2 (ja) * | 2000-06-15 | 2011-12-14 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | 抗hcv抗体についてのイムノアッセイ |
US7101683B2 (en) * | 2001-06-26 | 2006-09-05 | Abbott Laboratories | Methods for the simultaneous detection of HCV antigens and HCV antibodies |
US8546075B2 (en) * | 2003-10-28 | 2013-10-01 | Advanced Life Science Institute, Inc. | Method of detecting hepatitis C virus |
WO2007049394A1 (ja) * | 2005-10-25 | 2007-05-03 | Kurume University | C型肝炎ウイルス由来ペプチド |
US9841427B2 (en) | 2013-03-14 | 2017-12-12 | Abbott Laboratories | HCV antigen-antibody combination assay and methods and compositions for use therein |
US10444242B2 (en) | 2013-03-14 | 2019-10-15 | Abbott Laboratories | Detection methods employing HCV core lipid and DNA binding domain monoclonal antibodies |
US9790478B2 (en) | 2013-03-14 | 2017-10-17 | Abbott Laboratories | HCV NS3 recombinant antigens and mutants thereof for improved antibody detection |
US9194873B2 (en) | 2013-03-14 | 2015-11-24 | Abbott Laboratories | HCV antigen-antibody combination assay and methods and compositions for use therein |
US11428694B2 (en) | 2013-03-14 | 2022-08-30 | Abbott Laboratories | Detection methods employing HCV core lipid and DNA binding domain monoclonal antibodies |
US10197573B2 (en) | 2013-03-14 | 2019-02-05 | Abbott Laboratories | HCV core lipid binding domain monoclonal antibodies |
US10345311B2 (en) | 2013-03-14 | 2019-07-09 | Abbott Laboratories | Detection methods employing HCV core lipid and DNA binding domain monoclonal antibodies |
US10634676B2 (en) | 2015-10-15 | 2020-04-28 | Fujirebio Inc. | Method and kit for simultaneously detecting human parvovirus B19 antigen and antibody |
WO2017065261A1 (ja) * | 2015-10-15 | 2017-04-20 | 富士レビオ株式会社 | ヒトパルボウイルスb19抗原および抗体の同時検出方法及びキット |
JPWO2017065261A1 (ja) * | 2015-10-15 | 2018-08-02 | 富士レビオ株式会社 | ヒトパルボウイルスb19抗原および抗体の同時検出方法及びキット |
JP2019523863A (ja) * | 2016-05-31 | 2019-08-29 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ウイルス抗原の血清学的検出方法 |
JP2019522188A (ja) * | 2016-05-31 | 2019-08-08 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Hcvコア抗原の迅速な検出のための前処理法 |
US11150247B2 (en) | 2016-05-31 | 2021-10-19 | Roche Diagnostics Operations, Inc. | Method for serological detection of viral antigens |
JP7044721B2 (ja) | 2016-05-31 | 2022-03-30 | エフ.ホフマン-ラ ロシュ アーゲー | Hcvコア抗原の迅速な検出のための前処理法 |
JP2022058435A (ja) * | 2016-05-31 | 2022-04-12 | エフ.ホフマン-ラ ロシュ アーゲー | ウイルス抗原の血清学的検出方法 |
JP7308914B2 (ja) | 2016-05-31 | 2023-07-14 | エフ. ホフマン-ラ ロシュ アーゲー | ウイルス抗原の血清学的検出方法 |
Also Published As
Publication number | Publication date |
---|---|
ES2313787T3 (es) | 2009-03-01 |
DE69939811D1 (de) | 2008-12-11 |
EP1020727A1 (en) | 2000-07-19 |
KR100847586B1 (ko) | 2008-07-22 |
EP1020727B1 (en) | 2008-10-29 |
CA2305192C (en) | 2009-10-13 |
CN1274424A (zh) | 2000-11-22 |
BR9906660A (pt) | 2000-08-29 |
EP1020727A4 (en) | 2004-12-29 |
JP3514729B2 (ja) | 2004-03-31 |
KR20010024340A (ko) | 2001-03-26 |
US7316905B1 (en) | 2008-01-08 |
ATE412904T1 (de) | 2008-11-15 |
CA2305192A1 (en) | 2000-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000007023A1 (fr) | Procede pour la determination de l'hepatite a virus de type c | |
US7776542B1 (en) | Methods for the detection of hepatitis B and C viruses | |
KR102019008B1 (ko) | 메르스 코로나바이러스 뉴클레오캡시드 융합 단백질을 이용한 메르스 코로나바이러스 검출 방법 | |
JP4744298B2 (ja) | C型肝炎ウイルスの検出方法 | |
JP7198222B2 (ja) | B型肝炎ウイルスs抗原の測定方法及び測定キット | |
US5871904A (en) | Immunassay of non-A, non-B hepatitis virus-related antigens, monoclonal antibodies for use therein, and hybridomas producing the antibodies | |
US20080138794A1 (en) | Method for detecting or measuring HBV | |
US6623921B2 (en) | Method for measurement of hepatitis C virus | |
JP3536731B2 (ja) | HIV−1p24抗原の免疫測定方法及び試薬 | |
JP6808178B2 (ja) | ヒトパルボウイルスb19抗原および抗体の同時検出方法及びキット | |
EP2862876A1 (en) | Antibody binding to envelope protein 2 of hepatitis C virus and method for identifying genotype of hepatitis C virus using the same | |
JP2001124779A (ja) | Hcvコア抗原の検出または定量方法およびそれに用いる検出または定量試薬。 | |
JP2021524483A (ja) | E型肝炎ウイルスのORF2iタンパク質に対する特異性を有する抗体及び診断目的のためのその使用 | |
JP6037043B2 (ja) | TRACP−5b(酒石酸抵抗性酸性フォスファターゼ5b)に特異的なタンパク定量法 | |
WO2022057254A1 (zh) | Hcv重组抗原及其突变体 | |
JP3176570B2 (ja) | Hcvの検出又は測定方法 | |
CN112898415B (zh) | 一种检测新型冠状病毒的抗体及检测试剂盒 | |
CA2493558C (en) | Methods for detecting or assaying virus | |
WO2018119838A1 (zh) | Hiv重组抗原、表达基因、表达载体以及hiv检测试剂盒 | |
JP2001224371A (ja) | Hcvの検出又は測定方法 | |
KR20230124282A (ko) | 지카 바이러스의 비구조 단백질 1에 특이적인 진단용 항체 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 99801248.3 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL BR CA CN JP KR LT LV MK RO RU SI US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09509449 Country of ref document: US |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2305192 Country of ref document: CA Ref document number: 2305192 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020007003410 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999933204 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999933204 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007003410 Country of ref document: KR |
|
WWR | Wipo information: refused in national office |
Ref document number: 1020007003410 Country of ref document: KR |